Table 1.
Tenofovir-containing therapeutics for HIV and HBV.
| Disease | Drug (Common Name) | Launch |
|---|---|---|
| HIV/AIDS | Viread (TDF) | 2001 |
| Truvada® (TDF/emtricitabine) | 2004 | |
| Atripla® (TDF/emtricitabine/efavirenz) 1 | 2006 | |
| Complera® (TDF/emtricitabine/rilpivirine) 1 | 2011 | |
| Stribild® (TDF/emtricitabine/elvitegravir/cobicistat) 1 | 2012 | |
| Genvoya® (TAF/emtricitabine/elvitegravir/cobicistat) 1 | 2015 | |
| Odefsey® (TAF/emtricitabine/rilpivirine) 1 | 2016 | |
| Descovy® (TAF/emtricitabine) | 2016 | |
| Bitarvy® (TAF/emtricitabine/bictegravir) 1 | 2018 | |
| HIV PrEP 2 | Truvada (TDF/emtricitabine) | 2012 |
| Descovy (TAF/emtricitabine) | 2019 | |
| Hepatitis B | Hepsera (adefovir dipivoxil) | 2002 |
| Viread (TDF) | 2008 | |
| Vemlidy (TAF) | 2016 |
1 Single tablet regimens dosed as one pill once daily; 2 pre-exposure prophylaxis for the prevention of HIV transmission.